2023
DOI: 10.1101/2023.04.12.23288460
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization

Abstract: The non-invasive approach for early cancer detection promises a screening assay accessible for everyone. However, the delivery of this promise is limited due mostly to the high sequencing cost associated with available assays. Here, we developed a multimodal assay called SPOT-MAS (Screening for the Presence Of Tumor by Methylation And Size) to simultaneously profile methylomics, fragmentomics, copy number, and end motifs in a single workflow using targeted and shallow genome-wide sequencing of cell-free DNA. W… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
4
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(4 citation statements)
references
References 65 publications
(84 reference statements)
0
4
0
Order By: Relevance
“…QUADAS-2 assessments for each study of MCED tests currently available for use are summarised in Table 3. One study of each of Galleri, 31 CancerSEEK, 33 and SPOT-MAS 64 were case-control studies, which are considered to have a high risk of bias in the ‘patient selection’ domain of the QUADAS-2 checklist. 24 There was a high concern regarding the applicability of the index test for the studies evaluating CancerSEEK, as this test has been modified (now called Cancerguard™) and is undergoing further assessment.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…QUADAS-2 assessments for each study of MCED tests currently available for use are summarised in Table 3. One study of each of Galleri, 31 CancerSEEK, 33 and SPOT-MAS 64 were case-control studies, which are considered to have a high risk of bias in the ‘patient selection’ domain of the QUADAS-2 checklist. 24 There was a high concern regarding the applicability of the index test for the studies evaluating CancerSEEK, as this test has been modified (now called Cancerguard™) and is undergoing further assessment.…”
Section: Resultsmentioning
confidence: 99%
“…First CSO was correct for 83.3% (five out of six) of the cancers; the types of cancer detected by the SPOT-MAS test in the K-DETEK 8 study are presented in Appendix 7, Table 17. A case-control study 64 recruited 239 patients diagnosed with Stage I-IIIA cancers (see Appendix 7, Table 17 for the cancer types among recruited patients) and 474 healthy controls as a validation cohort for the SPOT-MAS test. Specificity of the SPOT-MAS test was high (97.0, 95% CI 95.1% to 98.4%) with only 14 out of the 474 healthy controls with FP results.…”
Section: Resultsmentioning
confidence: 99%
“…Large language models have recently made impressive strides in capturing patterns of social cognition [25,26,134–137], and various neural architectures have been able to capture some patterns of human Theory of Mind in gridworld tasks [138–140]. However, these models have yet to approach the logical and causal reasoning capacity that humans develop by childhood [139,141,142].…”
Section: Discussionmentioning
confidence: 99%
“…evaluation of large-scale multi-view 3D reconstruction with RANCOM technique [87], CRITIC technique [88][89][90][91][92], COMET technique [93][94][95][96][97][98], MAIRCA technique [99][100][101] and QUALIFLEX technique [102][103][104][105][106].…”
mentioning
confidence: 99%